Observation on the efficacy and safety of atezolizumab plus donafenib in the treatment of advanced unresectable hepatocellular carcinoma

XU Chen; YANG Zhikai; ZHANG Jingpo

doi:10.6039/j.issn.1001-0408.2026.19.11

您当前的位置：

首页 >

文章列表页 >

Observation on the efficacy and safety of atezolizumab plus donafenib in the treatment of advanced unresectable hepatocellular carcinoma

更新时间：2026-10-12

- Observation on the efficacy and safety of atezolizumab plus donafenib in the treatment of advanced unresectable hepatocellular carcinoma
- ZHONGGUO YAOFANG Vol. 37, Issue 19, Pages: 2550-2555(2026)
- 作者机构：
  
  河北医科大学第一医院肝胆胰外科，石家庄　050031
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.19.11
  CLC： R969.4;R735.7
- Received：14 July 2026，
  
  Revised：2026-09-21，
  
  Accepted：21 September 2026，
  
  Published：15 October 2026
- 稿件说明：
移动端阅览
徐晨,杨智凯,张敬坡.阿替利珠单抗联合多纳非尼治疗晚期不可切除肝细胞癌的疗效与安全性观察 [J].中国药房,2026,37(19):2550-2555.

XU Chen,YANG Zhikai,ZHANG Jingpo.Observation on the efficacy and safety of atezolizumab plus donafenib in the treatment of advanced unresectable hepatocellular carcinoma[J].ZHONGGUO YAOFANG,2026,37(19):2550-2555.
徐晨,杨智凯,张敬坡.阿替利珠单抗联合多纳非尼治疗晚期不可切除肝细胞癌的疗效与安全性观察 [J].中国药房,2026,37(19):2550-2555. DOI： 10.6039/j.issn.1001-0408.2026.19.11.

XU Chen,YANG Zhikai,ZHANG Jingpo.Observation on the efficacy and safety of atezolizumab plus donafenib in the treatment of advanced unresectable hepatocellular carcinoma[J].ZHONGGUO YAOFANG,2026,37(19):2550-2555. DOI： 10.6039/j.issn.1001-0408.2026.19.11.

摘要

目的

探索阿替利珠单抗联合多纳非尼治疗晚期不可切除肝细胞癌（uHCC）的疗效与安全性。

方法

选取2023年5月1日至2025年4月30日于河北医科大学第一医院肝胆胰外科就诊的uHCC患者为研究对象进行回顾性研究。所有患者均接受经导管动脉化疗栓塞术（TACE）和/或肝动脉灌注化疗术（HAIC）介入治疗，在此基础上按照系统治疗方案分为对照组（阿替利珠单抗+贝伐珠单抗，

＝56）和观察组（阿替利珠单抗+多纳非尼，

＝49）。比较两组患者的近期（治疗后3个月）疗效和远期疗效；进一步将性别、年龄、乙型肝炎、肝硬化、Child-Pugh分级、巴塞罗那临床肝癌（BCLC）分期、美国东部肿瘤协作组体能状态（ECOG-PS）评分、肿瘤数目、肿瘤最大直径、门静脉癌栓及介入方式作为亚组变量对总生存期进行分析，并对亚组变量与治疗组别进行交互作用检验；比较两组患者治疗期间的不良反应。

结果

治疗3个月后，观察组患者的疾病控制率显著高于对照组（

＜0.05），但两组在客观缓解率上的差异无统计学意义（

＞0.05）。对照组患者的中位无进展生存期为7.53个月[95%置信区间（CI）为6.32～8.53个月

]

，观察组为8.06个月（95%CI为7.33～9.70个月），两组比较的差异无统计学意义（

＞0.05）；对照组患者的中位总生存期为13.56个月（95%CI为11.23～15.77个月），观察组为14.92个月（95%CI为12.93～17.11个月），观察组显著长于对照组（

＜0.05）。亚组分析结果显示，在Child-Pugh A级、BCLC B期及未合并门静脉癌栓患者中，观察组相对于对照组的死亡风险较低，风险比分别为0.46、0.49和0.44，交互作用的

值分别为0.035、0.008和0.013。两组患者发生的不良反应总体以1～2级为主；各项不良反应发生率比较，差异均无统计学意义（

＞0.05）。

结论

对于接受介入治疗的晚期uHCC患者，阿替利珠单抗联合多纳非尼方案与较高的疾病控制率和较长的总生存期相关，这种关联主要见于Child-Pugh A级、BCLC B期及未合并门静脉癌栓的患者。

Abstract

OBJECTIVE

To investigate the efficacy and safety of atezolizumab plus donafenib in patients with advanced unresectable hepatocellular carcinoma （uHCC）.

METHODS

Patients with uHCC treated at the Dept. of Hepatobiliary and Pancreatic Surgery， The First Hospital of Hebei Medical University， from May 1， 2023 to April 30， 2025 were selected as

study subjects for a retrospective study. All patients received interventional therapy with transcatheter arterial chemoembolization （TACE） and/or hepatic arterial infusion chemotherapy （HAIC）. On this basis， patients were divided according to the systemic treatment regimen into a control group （atezolizumab plus bevacizumab，

＝56） and an observation group （atezolizumab plus donafenib，

＝49）. Short-term efficacy at 3 months after treatment and long-term efficacy were compared between the two groups. Subgroup analyses were further performed with sex， age， hepatitis B， liver cirrhosis， Child-Pugh class， Barcelona Clinic Liver Cancer （BCLC） stage， Eastern Cooperative Oncology Group Performance Status （ECOG-PS） score， tumor number， maximum tumor diameter， portal vein tumor thrombus， and interventional treatment modality as subgroup variables， with interaction tests conducted between subgroup variables and treatment group. Adverse reactions during treatment were compared between the two groups.

RESULTS

At 3 months after treatment， the disease control rate was significantly higher in the observation group than in the control group （

＜0.05）， whereas the difference in objective response rate between the two groups was not statistically significant （

＞0.05）. The median progression-free survival was 7.53 months [95% confidence interval （CI）： 6.32-8.53 months

]

in the control group and 8.06 months （95%CI： 7.33-9.70 months） in the observation group， with no statistically significant difference between the two groups （

＞0.05）. The median overall survival was 13.56 months （95%CI： 11.23-15.77 months） in the control group and 14.92 months （95%CI： 12.93-17.11 months） in the observation group， and overall survival was significantly longer in the observation group than in the control group （

＜0.05）. Subgroup analysis showed that among patients with Child-Pugh class A， BCLC stage B， or without portal v

ein tumor thrombus， the risk of death was lower in the observation group than in the control group， with hazard ratios of 0.46， 0.49 and 0.44， respectively， and interaction

values of 0.035， 0.008 and 0.013， respectively. Adverse reactions in both groups were mainly grade 1-2， and there were no statistically significant differences in the incidence of individual adverse reactions between the two groups （

＞0.05）.

CONCLUSIONS

In patients with advanced uHCC receiving interventional therapy， the atezolizumab plus donafenib regimen was associated with a higher disease control rate and longer overall survival， and this association was mainly observed in patients with Child-Pugh class A， BCLC stage B， or without portal vein tumor thrombus.

关键词

Keywords

references

Li P ， Ding Z ， Feng Y Q ， et al . Global，regional，and national burden of hepatocellular carcinoma and contribution of nine modifiable risk factors across 185 countries/territories in 2022 [J ] . Sci Bull ， 2026 ， 71 （ 4 ）： 838 - 849 .

邵明华，谭斌彬，付颖，等 . 钇-90树脂微球经动脉放射栓塞治疗初始不可切除肝脏恶性肿瘤的安全性和短期疗效 [J ] . 中华消化外科杂志， 2024 ， 23 （ 7 ）： 969 - 975 .

Xu H W ， Zhang H L ， Li B ， et al . Systemic conversion therapies for initially unresectable hepatocellular carcinoma：a systematic review and meta-analysis [J ] . BMC Cancer ， 2024 ， 24 （ 1 ）： 1008 .

Cillo U ， Caregari S ， Barabino M ， et al . Hierarchically positioning laparoscopic microwave ablation in the therapeutic span of early hepatocellular carcinoma：a real-life comparative analysis [J ] . Ann Surg Oncol ， 2025 ， 32 （ 2 ）： 1063 - 1072 .

Gigante E ， Bouattour M ， Bedoya J U ， et al . Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma：a multicentric retrospective study [J ] . United European Gastroenterol J ， 2024 ， 12 （ 4 ）： 429 - 439 .

Zhou H Y ， Song T Q . Conversion therapy and maintenance therapy for primary hepatocellular carcinoma [J ] . Biosci Trends ， 2021 ， 15 （ 3 ）： 155 - 160 .

Shannon A H ， Manne A ， Diaz Pardo D A ， et al . Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma [J ] . Front Oncol ， 2023 ， 13 ： 1193762 .

Kurebayashi Y ， Matsuda K ， Ueno A ， et al . Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments [J ] . Hepatology ， 2022 ， 75 （ 5 ）： 1139 - 1153 .

Chi Q Y ， Liu Q Y ， Wang S J ， et al . Lenvatinib combined with anti-PD-1 antibodies plus locoregional treatment for initial unresectable hepatocellular carcinoma with portal vein tumor thrombosis：a multicenter real-world study [J ] . BMC Cancer ， 2025 ， 25 （ 1 ）： 1162 .

Qin S K ， Bi F ， Gu S Z ， et al . Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma：a randomized，open-label，parallel-controlled phase Ⅱ-Ⅲ trial [J ] . JCO ， 2021 ， 39 （ 27 ）： 3002 - 3011 .

国家卫生健康委员会医政司 . 原发性肝癌诊疗指南：2024年版 [J ] . 协和医学杂志， 2024 ， 15 （ 3 ）： 532 - 559 .

Reig M ， Forner A ， Rimola J ， et al . BCLC strategy for prognosis prediction and treatment recommendation：the 2022 update [J ] . J Hepatol ， 2022 ， 76 （ 3 ）： 681 - 693 .

Mojsak D ， Kuklińska B ， Minarowski Ł ， et al . Current state of knowledge on immunotherapy in ECOG PS 2 patients：a systematic review [J ] . Adv Med Sci ， 2021 ， 66 （ 2 ）： 381 - 387 .

Yoshitomi K ， Hayashi T ， Oe S ， et al . Child-Pugh grade deterioration stratified by the etiology after transcatheter arterial chemoembolization as initial treatment for hepatocellular carcinoma [J ] . Sci Rep ， 2024 ， 14 （ 1 ）： 3707 .

Yu H L ， Bai Y P ， Xie X Y ， et al . RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma：a systematic review and meta-analysis [J ] . BMJ Open ， 2022 ， 12 （ 6 ）： e052294 .

Bouziane J ， Loap P ， Allali S ， et al . Concurrent trastuzumab deruxtecan and radiation therapy in HER2-positive and HER2-low metastatic breast cancer：assessing the efficacy [J ] . Am J Clin Oncol ， 2026 ， 49 （ 1 ）： 33 - 38 .

Ye Q W ， Song Z R ， Yu T D ， et al . Triple therapy with interventional treatment，donafenib，and anti-PD-1 antibo- dies in unresectable hepatocellular carcinoma：a retrospective real-world study in China [J ] . J Hepatocellular Carcinoma ， 2025 ， 12 ： 1905 - 1919 .

Li J P ， Li Y ， Li Y M ， et al . Efficacy and liver function preservation with donafenib combined with transarterial chemoembolization in unresectable hepatocellular carcinoma：an ALBI grade analysis [J ] . Front Oncol ， 2025 ， 15 ： 1612477 .

Shi H ， Shao W ， Song J Y ， et al . Graph attention network enables multipurpose prediction of imaging mass cytome- try in a hepatocellular carcinoma clinical trial [J ] . Intell Oncol ， 2025 ， 1 （ 4 ）： 326 - 340 .

Yan H Z ， Li G H ， Zhao C H ， et al . Donafenib vs. lenvatinib combined with transarterial chemoembolization as initial therapy for unresectable hepatocellular carcinoma：a retrospective real-world study [J ] . Quant Imaging Med Surg ， 2025 ， 15 （ 8 ）： 7235 - 7245 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical observation of sacituzumab tirumotecan combined with bevacizumab in the treatment of HER2-negative breast cancer with brain metastases

Efficacy of finerenone combined with Shenkangning capsules in diabetic kidney disease patients with spleen-kidney yang deficiency and blood stasis syndrome

Efficacy and safety of different classes of antibacterial agents for hospitalized adult patients with community-acquired pneumonia： a network meta-analysis

Efficacy of toludesvenlafaxine in the treatment of patients with major depressive disorder with anhedonia

Study on the efficacy and safety of 3 kinds of novel biologics in the treatment of Crohn’s disease

Related Author

YANG Yufeng

YANG Xiuli

CHENG Peng

SHEN Ling

YANG Qian

SHAO Yingbo

WANG Yangyang

ZHANG Yaqi

Related Institution

Dept. of Breast Surgery， Henan Provincial People’s Hospital

Dept. of Oncology， The First Affiliated Hospital of Nanyang Medical College

Dept. of Pharmacy， The First Affiliated Hospital of Nanyang Medical College

Dept. of Nephrology，Changzhou Wujin Hospital of Traditional Chinese Medicine （Wujin Affiliated Hospital of Nanjing University of Chinese Medicine）

Dept. of Endocrinology，Changzhou Wujin Hospital of Traditional Chinese Medicine（Wujin Affiliated Hospital of Nanjing University of Chinese Medicine）

⁰